Creative Biolabs Unveils One-stop TCR Development Services for Research on TCR-T Therapy

February 22 22:15 2021
Up to now, several immunotherapies have been developed, and in current stages, TCR therapy is a more versatile method that can be applied to more cancers. With years of exploration in TCR technologies, Creative Biolabs now launches one-stop TCR-T therapy development services.

New York, USA – February 22, 2021 – Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumor development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. TCR-T therapy transfers TCR genes that can specifically bind to antigens into T lymphocytes, so that they can bind to tumor cells expressing the antigen and induce T cells to kill tumor cells.

Supported by in-house scientists and first-in-class TCR development platforms, Creative Biolabs now offers a broad range of custom TCR-T early development services, covering biomarker identification and selection, design and construction, TCR gene packaging and delivery, generation and optimization, as well as in vitro and in vivo assays.

TCR Design & Construction

With accumulated experience in the general method of TCR construction, the scientist team at Creative Biolabs has optimized the construction strategies, combining the conventional steps into a single process, which greatly streamlines the TCR vector production process.

Creative Biolabs also provides customized design and construction of TCR products for clients to meet every special need, including a plethora of TCR-like antibody products, TCR-like CAR products, TCR Jurkat cell products, TCR vector products, and antibody-TCR (AbTCR) vector products.

TCR Generation & Optimization

Creative Biolabs has unveiled several cutting-edge approaches to generate TCRs specific for the antigens that are expressed by a wide range of tumor cell types and to optimize strategies of increasing TCR affinity.

TCR generation platforms facilitate the obtaining of TCR generated from tumor infiltrating lymphocytes (TIL), from phage display, or from in vivo system. For TCR optimization, Creative Biolabs is skillful at three classics strategies, which are TCR C region murinization, incorporation of additional cysteine residue, and increasing avidity. Besides, a platform for affinity maturation service is also available to achieve a higher TCR affinity mature level for clients’ programs.

With the availability of profound TCR knowledge, certified technical staff and numerous state-of-the-art instruments, other services mentioned above are also available with a high level of customization. More information can be reached on https://www.creative-biolabs.com/car-t.

About Creative Biolabs

With more than 15 years’ history, Creative Biolabs has gathered talented scientists working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, Creative Biolabs specializes in the one-stop custom services for CAR-T cell development, TCR modified T cell development, CAR-macrophage therapy development, cancer vaccine development, drug discovery for CRS management, etc.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/car-t